ADC Therapeutics To Participate In The Guggenheim SMID Cap Biotech Conference
Date
1/30/2025 7:16:43 AM
(MENAFN- PR Newswire)
LAUSANNE, Switzerland, Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT ), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech conference on Thursday, February 6, 2025, at 2:00 p.m. ET.
A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT ) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit the Company website at adctherapeutics and follow us on LinkedIn .
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
[email protected]
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
[email protected]
+1 862-926-9040
SOURCE ADC Therapeutics SA
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN30012025003732001241ID1109148517
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.